"Health Insurance Broker"

For the first time, scientists have tracked the activity, across the lifespan, of an environmentally responsive regulatory mechanism that turns genes on and off in the brain’s executive hub. Among key findings of the study by National Institutes of Health scientists: genes implicated in schizophrenia and autism turn out to be members of a select club of genes in which regulatory activity peaks during an environmentally-sensitive critical period in development…

‘Tuberculosis patients may receive treatments in the future according to what version they have of a single ‘Goldilocks’ gene, says an international research team from Oxford University, King’s College London, Vietnam and the USA. This is one of the first examples in infectious disease of where an individual’s genetic profile can determine which drug will work best for them – the idea of personalised medicine that is gradually becoming familiar in cancer medicine…

It can be difficult to distinguish between people with normal age-associated memory loss and those with amnestic mild cognitive impairment (aMCI). However people with aMCI are at a greater risk of developing Alzheimer’s disease (AD), and identification of these people would mean that they could begin treatment as early as possible. New research published in BioMed Central’s open access journal BMC Geriatrics shows that specific questions, included as part of a questionnaire designed to help diagnose AD, are also able to discriminate between normal memory loss and aMCI…